Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
CytomX history
CytomX company history timeline
Since joining Pfizer Ventures as executive director in 2008, Doctor Jones was responsible for making and managing venture investments for Pfizer as well as serving in Board roles for several and therapeutic companies.
Since joining the company in 2009, he held multiple positions in research and development and led the growth of the company’s therapeutic pipeline.
During Dr Lambert’s tenure in leadership roles at ImmunoGen, the company invented the ADC technology that resulted in the Genentech/Roche drug, Kadcyla® (approved in 2013 for treating HER2+ breast cancer), as well as numerous other ADCs taken into clinical development.
At the Freiburg Institute for Advanced Studies, Albert-Ludwigs Universität Freiburg, Germany he was an External Senior Fellow, and in November 2014 was appointed as an Honorary Professor, Albert-Ludwigs-Universität Freiburg.
Danielle T. Olander joined CytomX in 2014, and serves as senior vice president of talent and systems development.
He was elected to the HUPO Council and to the Executive Committee of the Chromosome–Centric Human proteome Project (CHPP) in 2014.
In 2015, he joined the board of directors of PRA Health Sciences Inc., a contract research company.
Meyers has served as a Senior Advisor to Gilead Sciences since his retirement from Gilead in February 2018.
Doctor Belvin joined CytomX in 2018.
Doctor Elaine Jones retired in April 2019 from her role as vice president, worldwide business development and senior partner at Pfizer Ventures, the venture capital arm of Pfizer Inc.
Matthew P. Young was appointed chief operating officer and chief financial officer of GRAIL in October 2019.
He is recipient of the 2019 AACR Distinguished Public Service Award.Weiner earned his bachelor degree in biology with honors from the University of Pennsylvania and his M.D. from Mount Sinai School of Medicine.
Rate CytomX's efforts to communicate its history to employees.
CytomX jobs
Do you work at CytomX?
Is CytomX's vision a big part of strategic planning?
CytomX competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| MacroGenics | 2000 | $150.0M | 307 | 9 |
| Ardelyx | 2007 | $333.6M | 86 | 61 |
| Synlogic | 2014 | $8,000 | 74 | - |
| Syros Pharmaceuticals | 2012 | $9.9M | 124 | - |
| Ophthotech | 2007 | $210.0M | 58 | - |
| Omeros | 1994 | $29.9M | 265 | 4 |
| Genocea | 2006 | - | 59 | - |
| CRISPR Therapeutics | 2013 | $37.3M | 304 | 33 |
| Blueprint Medicines | 2011 | $508.8M | 495 | 6 |
| AnaptysBio | 2005 | $91.3M | 78 | 1 |
CytomX history FAQs
Zippia gives an in-depth look into the details of CytomX, including salaries, political affiliations, employee data, and more, in order to inform job seekers about CytomX. The employee data is based on information from people who have self-reported their past or current employments at CytomX. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by CytomX. The data presented on this page does not represent the view of CytomX and its employees or that of Zippia.
CytomX may also be known as or be related to CYTOMX THERAPEUTICS INC., CytomX, CytomX Therapeutics, CytomX Therapeutics Inc, CytomX Therapeutics, Inc., Cytomx Therapeutics and Cytomx Therapeutics, Inc.